Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
January 21, 2022

Senhwa Biosciences receives ODD for Silmitasertib from FDA to treat biliary tract cancer

Senhwa Biosciences has announced the receipt of Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients with biliary tract cancer (BTC).

ODD status is given to those drugs and biologics meant for treatment, prevention or diagnosis of a life-threatening or chronically debilitating rare disease. Credit:  Michal Jarmoluk from Pixabay